New insights in antiplatelet therapy for patients with ischemic stroke

Seemant Chaturvedi, Pratik Bhattacharya

Research output: Contribution to journalArticle

4 Citations (Scopus)

Abstract

Background: Acute treatment and long-term secondary prevention of noncardioembolic ischemic stroke and transient ischemic attack (TIA) include initiation of antiplatelet therapy. Antiplatelet agents currently used in the treatment of ischemic stroke and TIA are aspirin, clopidogrel, and dipyridamole. Review Summary: The safety and efficacy of antiplatelet therapy in patients with ischemic stroke, including a discussion of recent trial data and its influence on treatment guidelines, are presented. A brief discussion of the use of antiplatelet therapy in preventing stroke and embolism in patients with atrial fibrillation is also presented. For secondary prevention of ischemic events in patients with a history of stroke, clinical trials have shown the addition of dipyridamole to aspirin to be more effective than aspirin alone. The therapies are also similar from a standpoint of bleeding. The combination of aspirin and clopidogrel was not shown to be more efficacious and caused more bleeding than aspirin alone when evaluated for secondary prevention. However, dual antiplatelet therapy with aspirin and clopidogrel may have some benefit in the acute stroke setting or in the prevention of thrombotic events in patients with atrial fibrillation who cannot or will not take warfarin. Conclusions: Antiplatelet therapy is an important component of acute and long-term treatment of ischemic stroke and TIA. Ongoing clinical trials may help to refine what treatment regimens are best suited for acute and long-term therapy.

Original languageEnglish (US)
Pages (from-to)255-262
Number of pages8
JournalNeurologist
Volume17
Issue number5
DOIs
StatePublished - Sep 2011
Externally publishedYes

Fingerprint

Stroke
clopidogrel
Aspirin
Transient Ischemic Attack
Therapeutics
Secondary Prevention
Dipyridamole
Atrial Fibrillation
Clinical Trials
Hemorrhage
Platelet Aggregation Inhibitors
Warfarin
Embolism
Guidelines
Safety

Keywords

  • antiplatelet therapy
  • ischemic stroke
  • secondary prevention
  • transient ischemic attack

ASJC Scopus subject areas

  • Clinical Neurology

Cite this

New insights in antiplatelet therapy for patients with ischemic stroke. / Chaturvedi, Seemant; Bhattacharya, Pratik.

In: Neurologist, Vol. 17, No. 5, 09.2011, p. 255-262.

Research output: Contribution to journalArticle

Chaturvedi, Seemant ; Bhattacharya, Pratik. / New insights in antiplatelet therapy for patients with ischemic stroke. In: Neurologist. 2011 ; Vol. 17, No. 5. pp. 255-262.
@article{eb5f6e42e8cb454882f5dc09d2eabd68,
title = "New insights in antiplatelet therapy for patients with ischemic stroke",
abstract = "Background: Acute treatment and long-term secondary prevention of noncardioembolic ischemic stroke and transient ischemic attack (TIA) include initiation of antiplatelet therapy. Antiplatelet agents currently used in the treatment of ischemic stroke and TIA are aspirin, clopidogrel, and dipyridamole. Review Summary: The safety and efficacy of antiplatelet therapy in patients with ischemic stroke, including a discussion of recent trial data and its influence on treatment guidelines, are presented. A brief discussion of the use of antiplatelet therapy in preventing stroke and embolism in patients with atrial fibrillation is also presented. For secondary prevention of ischemic events in patients with a history of stroke, clinical trials have shown the addition of dipyridamole to aspirin to be more effective than aspirin alone. The therapies are also similar from a standpoint of bleeding. The combination of aspirin and clopidogrel was not shown to be more efficacious and caused more bleeding than aspirin alone when evaluated for secondary prevention. However, dual antiplatelet therapy with aspirin and clopidogrel may have some benefit in the acute stroke setting or in the prevention of thrombotic events in patients with atrial fibrillation who cannot or will not take warfarin. Conclusions: Antiplatelet therapy is an important component of acute and long-term treatment of ischemic stroke and TIA. Ongoing clinical trials may help to refine what treatment regimens are best suited for acute and long-term therapy.",
keywords = "antiplatelet therapy, ischemic stroke, secondary prevention, transient ischemic attack",
author = "Seemant Chaturvedi and Pratik Bhattacharya",
year = "2011",
month = "9",
doi = "10.1097/NRL.0b013e318224ed70",
language = "English (US)",
volume = "17",
pages = "255--262",
journal = "Neurologist",
issn = "1074-7931",
publisher = "Lippincott Williams and Wilkins",
number = "5",

}

TY - JOUR

T1 - New insights in antiplatelet therapy for patients with ischemic stroke

AU - Chaturvedi, Seemant

AU - Bhattacharya, Pratik

PY - 2011/9

Y1 - 2011/9

N2 - Background: Acute treatment and long-term secondary prevention of noncardioembolic ischemic stroke and transient ischemic attack (TIA) include initiation of antiplatelet therapy. Antiplatelet agents currently used in the treatment of ischemic stroke and TIA are aspirin, clopidogrel, and dipyridamole. Review Summary: The safety and efficacy of antiplatelet therapy in patients with ischemic stroke, including a discussion of recent trial data and its influence on treatment guidelines, are presented. A brief discussion of the use of antiplatelet therapy in preventing stroke and embolism in patients with atrial fibrillation is also presented. For secondary prevention of ischemic events in patients with a history of stroke, clinical trials have shown the addition of dipyridamole to aspirin to be more effective than aspirin alone. The therapies are also similar from a standpoint of bleeding. The combination of aspirin and clopidogrel was not shown to be more efficacious and caused more bleeding than aspirin alone when evaluated for secondary prevention. However, dual antiplatelet therapy with aspirin and clopidogrel may have some benefit in the acute stroke setting or in the prevention of thrombotic events in patients with atrial fibrillation who cannot or will not take warfarin. Conclusions: Antiplatelet therapy is an important component of acute and long-term treatment of ischemic stroke and TIA. Ongoing clinical trials may help to refine what treatment regimens are best suited for acute and long-term therapy.

AB - Background: Acute treatment and long-term secondary prevention of noncardioembolic ischemic stroke and transient ischemic attack (TIA) include initiation of antiplatelet therapy. Antiplatelet agents currently used in the treatment of ischemic stroke and TIA are aspirin, clopidogrel, and dipyridamole. Review Summary: The safety and efficacy of antiplatelet therapy in patients with ischemic stroke, including a discussion of recent trial data and its influence on treatment guidelines, are presented. A brief discussion of the use of antiplatelet therapy in preventing stroke and embolism in patients with atrial fibrillation is also presented. For secondary prevention of ischemic events in patients with a history of stroke, clinical trials have shown the addition of dipyridamole to aspirin to be more effective than aspirin alone. The therapies are also similar from a standpoint of bleeding. The combination of aspirin and clopidogrel was not shown to be more efficacious and caused more bleeding than aspirin alone when evaluated for secondary prevention. However, dual antiplatelet therapy with aspirin and clopidogrel may have some benefit in the acute stroke setting or in the prevention of thrombotic events in patients with atrial fibrillation who cannot or will not take warfarin. Conclusions: Antiplatelet therapy is an important component of acute and long-term treatment of ischemic stroke and TIA. Ongoing clinical trials may help to refine what treatment regimens are best suited for acute and long-term therapy.

KW - antiplatelet therapy

KW - ischemic stroke

KW - secondary prevention

KW - transient ischemic attack

UR - http://www.scopus.com/inward/record.url?scp=80052619237&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=80052619237&partnerID=8YFLogxK

U2 - 10.1097/NRL.0b013e318224ed70

DO - 10.1097/NRL.0b013e318224ed70

M3 - Article

C2 - 21881467

AN - SCOPUS:80052619237

VL - 17

SP - 255

EP - 262

JO - Neurologist

JF - Neurologist

SN - 1074-7931

IS - 5

ER -